BUZZ-US-listed Novo shares slip after company flags sharp 2026 sales drop
Reuters02-04
BUZZ-US-listed Novo shares slip after company flags sharp 2026 sales drop
** U.S.-listed shares of Danish drugmaker Novo NordiskNOVOb.CO fall 13.8% to $50.83
** Novo expects 2026 sales to fall between 5% and 13%, as competition in obesity drugs intensifies; analysts on average expect sales to decline 2% for the year
** Q4 operating profit down 14% at 31.7 billion crowns, while analysts estimate 31.2 billion
** Shares of rival Eli Lilly LLY.N fall 3.4% in afternoon trading
** Obesity drug developers Structure TherapeuticsGPCR.O and Altimmune ALT.O down 5.4% each, Viking Therapeutics VKTX.O down 3.7%, Amgen AMGN.O slip 1.4%
** Novo shares down ~42% in 2025
($1 = 6.3190 Danish crowns)
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments